Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04800185 · ClinicalTrials.gov registry record · Early Phase 1
Characterizing Skin Microbiome Change in Atopic Dermatitis
A Early Phase 1 study, sponsored by University of California, Irvine.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
NCT04800185 is a Early Phase 1 study that has completed, run by University of California, Irvine. The registered enrollment target is 20 participants.
The verdict
NCT04800185, a Early Phase 1 study, has completed, sponsored by University of California, Irvine.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
Atopic dermatitis (AD), also known as eczema, is an inflammatory disease of the skin affecting a large proportion of the pediatric and adult patient population. Chronic itching and eczematous lesions lead to a high burden of disease and associated patient morbidity with higher infection rates, emotional stress and associated psychological disease. The microbiome community contributes to human health through several mechanisms. Current research suggests that derangements in the normal microbiota may lead to inflammatory bowel disease, allergy, and metabolic syndromes. Specific to dermatology, new literature has demonstrated that changes in the microbiome may play a role in the development of atopic dermatitis. With this study, the investigators hope to characterize the baseline atopic dermatitis skin microbiome and monitor the evolution of the participants skin microbiome during and after treatment with anti-inflammatory topical medications, specifically the Food and Drug Administration (FDA)-approved phosphodiesterase inhibitor, crisaborole ointment 2% (Eucrisa).
Interventions
- DRUG Crisaborole 2% Top Oint
- GENETIC Skin Microbiome Swabs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2021-03-23 |
| Est. Completion | 2022-04-30 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04800185
The ClinicalTrials.gov registry entry for NCT04800185 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Irvine, which has 368 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Crisaborole 2% Top Oint is the first listed.
NCT04800185 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04800185 about?
NCT04800185 is a clinical study titled "Characterizing Skin Microbiome Change in Atopic Dermatitis". Atopic dermatitis (AD), also known as eczema, is an inflammatory disease of the skin affecting a large proportion of the pediatric and adult patient population. Chronic itching and eczematous lesions lead to a high burden of disease and associated patient morbidity with higher infection rates, emoti...
What is the current status of trial NCT04800185?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2021-03-23. Estimated completion is 2022-04-30.
What interventions are being tested in trial NCT04800185?
The interventions under investigation include: Crisaborole 2% Top Oint (DRUG), Skin Microbiome Swabs (GENETIC).
Who is sponsoring clinical trial NCT04800185?
This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.